Subscribe
m-a-istock-537908812
designer491 / iStockphoto.com
3 April 2018Asia-Pacific

Takeda mulls Shire acquisition bid

Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility